Products FTY720
FTY720 Approved Completed 🔥 Hot Apr 29, 2012 → Dec 12, 2016
About FTY720 FTY720 is a approved stage product being developed by Novartis for Multiple Sclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT01585298. Target conditions include Multiple Sclerosis.
Clinical Trials (11) NCT ID Phase Status Start Completion Indication NCT01585298 Approved Completed Apr 29, 2012 Dec 12, 2016 Multiple Sclerosis NCT01127750 Phase 3 Completed May 1, 2010 Oct 1, 2011 Relapsing Multiple Sclerosis NCT00416845 Phase 1 Completed Oct 1, 2006 — Healthy NCT00239876 Phase 3 Completed May 1, 2005 — Renal Transplantation NCT00099801 Phase 3 Completed Jan 1, 2005 Mar 1, 2006 Kidney Transplantation NCT00239798 Phase 2 Completed Nov 1, 2004 — Renal Transplantation NCT00239863 Phase 3 Completed May 1, 2004 — Renal Transplantation NCT00239811 Phase 3 Completed Apr 1, 2004 — Renal Transplantation NCT00098735 Phase 3 Completed Apr 1, 2004 — Kidney Transplantation NCT00239785 Phase 3 Completed Apr 1, 2003 — Renal Transplantation NCT00239902 Phase 2 Completed May 1, 2002 — Renal Transplantation
Product Company Stage Hype Score Placebo + Pirtobrutinib Eli Lilly Phase 2 Abemaciclib, dexamethasone, ixazomib, pomalidomide + Enasidenib, dexamethasone, ixazomib, pomalidomide + Cobimetinib, dexamethasone, ixazomib, pomalidomide + Erdafitinib, dexamethasone, ixazomib, pomalidomide + Venetoclax, dexamethasone, ixazomib, pomalidomide + Daratumumab, dexamethasone, ixazomib, pomalidomide + Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide + Selinexor, dexamethasone, ixazomib, pomalidomide Eli Lilly Phase 1/2 NEX-20A Nanexa AB Phase 1 agenT-797 MiNK Therapeutics Phase 1 Duloxetine Hydrochloride (HCI) + Placebo Eli Lilly Phase 3 Temferon Genenta Science Phase 1/2 CT-P44(Daratumumab) + Darzalex Faspro(Daratumumab) Celltrion Phase 3 CT-P53 + US-Ocrevus + EU-Ocrevus Celltrion Phase 3 CS-0777 tablets + CS-0777 tablets + CS-0777 tablets Daiichi Sankyo Phase 1 ASP7487, Velcade, Dexamethasone Astellas Pharma Phase 1/2 PHE885 Novartis Phase 2 Mirabegron + Placebo Astellas Pharma Approved Solifenacin Succinate + Solifenacin Succinate + Oxybutynin Hydrochloride + Placebo Astellas Pharma Approved Denileukin Diftitox (Ontak) Eisai Phase 1 Palonosetron Eisai Phase 2 BIW-8962 Kyowa Kirin Phase 1 KRN125(pegfilgrastim), PLR001(plerixafor) + KRN8601(filgrastim), PLR001(plerixafor) Kyowa Kirin Phase 2 KW-2478 + Bortezomib Kyowa Kirin Phase 1/2 ONO-2808 + Placebo Ono Pharmaceutical Phase 2 KW-2478 Kyowa Kirin Phase 1
Other Products from Novartis